MMA
MRNA icon

Miracle Mile Advisors’s Moderna MRNA Stock Holding History

Miracle Mile Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,846
Closed -$219K – 540
2024
Q2 		$219K Buy
+1,846
New +$234K 0.01% 455
2023
Q4 		– Sell
-2,589
Closed -$267K – 514
2023
Q3 		$267K Sell
2,589
-51
-2% -$5.69K 0.01% 412
2023
Q2 		$321K Buy
2,640
+150
+6% +$20K 0.01% 413
2023
Q1 		$382K Buy
2,490
+42
+2% +$6.93K 0.01% 398
2022
Q4 		$440K Hold
2,448
– – 0.02% 379
2022
Q3 		$289K Buy
+2,448
New +$371K 0.01% 373
2022
Q2 		– Sell
-1,239
Closed -$213K – 474
2022
Q1 		$213K Buy
1,239
+420
+51% +$70.7K 0.01% 433
2021
Q4 		$208K Sell
819
-42
-5% -$12.3K 0.01% 426
2021
Q3 		$331K Buy
+861
New +$318K 0.02% 346

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Miracle Mile Advisors's MRNA Position: Q3 2024 in Review

Miracle Mile Advisors sold out of Moderna (MRNA) in Q3 2024, closing a stake of 1,846 shares — an estimated $219K sold.

Miracle Mile Advisors first reported a position in MRNA in Q3 2021 and held it in 9 quarters. The position peaked at $440K in Q4 2022. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Miracle Mile Advisors reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Miracle Mile Advisors sold 1,846 Moderna shares in Q3 2024, an estimated $219K.
  • Miracle Mile Advisors first reported a position in Moderna in Q3 2021 and held it in 9 quarters.
  • Miracle Mile Advisors's Moderna position peaked at $440K in Q4 2022.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Miracle Mile Advisors's 13F filing for Q3 2024, filed 7 Oct 2024.